Document |
Document Title |
JP2010538072A |
This application is directed to the use of steroid compounds for the selective inhibition of the enzyme PTP1B in a mammal for the treatment of diabetes.
|
JP4564108B2 |
Deoxynojirimycin derivatives containing a large hydrophobic moiety, such as cholesterol or adamantame-methanol, linked through a spacer, such as pentamethylene, to the nitrogen atom of deoxynojirimycin, and salts thereof, inhibit glucosy...
|
JP4563578B2 |
The invention is directed to a novel class of steroids which exhibit potent antiprogestational activity.
|
JP4545929B2 |
The invention is directed to a novel class of steroids which exhibit potent antiprogestational activity.
|
JP4545930B2 |
The invention is directed to 17 beta -nitro-11 beta -arylsteroids of formula I: wherein R1, R6, R7, R12 and X are as defined by the specification. The compounds exhibit potent antiprogestational activity and are useful in the treatment o...
|
JP2010193809A |
To provide a method for producing a feeding center-suppressing substance.The method for producing the feeding center-suppressing substance comprises a step of fermenting a caralluma fruit and caffeine with lactobacillus. The feeding cent...
|
JP4541166B2 |
Methods and compositions for interacting with the GABAA receptor complex to induce sleep in humans using certain 5 3 alpha -hydroxy-5-reduced steroid derivatives.
|
JP4530851B2 |
The present invention relates (a) to new compounds represented by Formula I: wherein M represents a macrolide subunit (macrolide moiety) derived from macrolide possessing the property of accumulation in inflammatory cells, V represents a...
|
JP4509380B2 |
A process for the preparation of a compound of the formulawherein the substituents are defined as in the specification.
|
JP4507024B2 |
|
JP4495456B2 |
There are provided compounds of formula (I) wherein R1 represents O, S or NH; R2 represents -C(-O)-aryl or -C(-O)-heteroaryl; R3 represents hydrogen, methyl (which may be in either the alpha or beta configuration) or methylene; R4 and R5...
|
JP4486363B2 |
The invention relates to substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, of general formula (I), wherein R1 represents C7-C22 alkyl, C2-C4 alkyl that is substituted by C4-C20 alkoxy, C6-C10 aryl, C6-C10 aryloxy or C4-C12-alkoxy-C2-...
|
JP4476480B2 |
A compound selected from the group consisting of a compound of the formulawherein the substituents are defined as set forth in the specification which compounds are useful for the treatment of osteoporosis.
|
JP4470197B2 |
Amphoteric sterol derivatives, and liposomes containing these derivatives are new. The amphoteric sterol derivatives have an isoelectric point of 4.5-8.5 and are compounds of formula (I): Amphoter-Y-spacer-X-sterol (I) X and Y : linking ...
|
JP4474101B2 |
The present invention relates to novel compounds represented by the structure I and pharmaceutical preparations thereof for the treatment of inflammatory diseases in humans and animals.
|
JP2010095528A |
To provide a non-thermally reversible photochromic compound.The invention relates to a photochromic compound which may be thermally reversible or non-thermally reversible, and the like. The invention also relates to a photochromic dichro...
|
JP4436041B2 |
According to one aspect of the invention, there is provided a compound of formula (I) and solvates thereof. There are also provided compositions containing the compound, processes for preparing it, and its use in therapy.
|
JP2010031062A |
To provide a method and medicinal composition for treating disorders involving a ceramide-mediated signaling transmission system, for example, those selected from the group consisting of Gaucher disease, Tay-Sachs disease, Sandhoff disea...
|
JP2010024238A |
To provide an enzyme inhibitor strongly inhibiting 17-hydroxylase/C17,20-lyase and 5-reductase, blocking all androgen synthesis, and useful in treatment of prostatic cancer and benign prostatic hypertrophy, based on defects associated wi...
|
JP2010501575A |
Methods and compositions for treating cancer are described herein. More particularly, the methods for treating cancer comprise administering a 17α-hydroxylase/C17,20-lyase inhibitor, such as abiraterone acetate (i.e., 3β-acetoxy-17-(3-...
|
JP2009256388A |
To provide a new hybrid drug for cancer treatment and for releasing the drug by setting a target on cancer cells.Provided is a hybrid drug for cancer treatment, having a targeting moiety specifically bonding with proteins, receptors and ...
|
JP4357597B2 |
The invention relates to a method of preparing a compound of the general formula fac-ÄM(CO)3(OH2)3Ü<+> wherein M is Mn, <99m>Tc, <186>Re or <188>Re, by reacting a metal in the permetallate form with carbon monoxide and a reducing agent...
|
JP4338306B2 |
The invention relates to the steroidal saponin compounds for the propylaxis or treatment dementia, the new steroidal saponin compounds and the pharmaceutical composition containing the same.
|
JP4335820B2 |
17alpha -Alkyl-11beta -halo-17beta -oxy-estratriene derivatives (I), having a 7alpha -side-chain, are new. 17alpha -Alkyl-11beta -halo-17beta -oxy-estratriene derivatives of formula (I), their acid addition salts and esters are new. [Ima...
|
JP4324249B2 |
This invention describes the new 17alpha-fluoroalkyl steroids of general formula I as well as their physiologically compatible salts with bases. The new compounds have an extraordinary strong antigestagenic action and are suitable for th...
|
JP4308824B2 |
A method for preparing a 1-androstene derivative which comprises reacting a 2-iodo-androstane derivative with an oxidizing agent while maintaining the pH of the reaction mixture at a specific range gives the 1-androstene derivative with ...
|
JP4297994B2 |
6-Hydroxy and 6-oxo-androstane derivatives having the general formula (I): wherein the symbol @ represents a single or a double bond and A, R<1> and R<2> have the meanings given in the description; a pharmaceutical composition comprising...
|
JP2009143963A |
To provide a pharmaceutical composition for treating tumor, using hedgehog/smoothened signals for inhibiting apoptosis of tumor cells.The pharmaceutical composition contains a sufficient amount of cyclopamine, its pharmaceutically accept...
|
JP2009522383A |
The invention features compounds of formulas I or II: and pharmaceutically acceptable salts and prodrugs thereof, as well methods for modulating the effects of local and systemic hypoxic events using the compounds.
|
JP2009102413A |
To provide a method for administering a glucocorticoid receptor antagonist to a patient receiving AP regimen for a long term.The present invention generally pertains to the field of psychiatry. In particular, the present invention pertai...
|
JP2009517425A |
Sulfonamide prodrugs (I) are new. Sulfonamide prodrugs of fromula (I) are new Drug-OCO-X-SO 2NH 2 (I) X : optionally substituted heteroaromatic group or alkyl-heteroaromatic group; Drug : pharmaceutical able to form a carboxylate ester t...
|
JP2009515828A |
The disclosure provides androsterone derivatives. The derivatives of the disclosure are useful in the treatment of androgen- and estrogen-associated diseases and disorders, including breast cancer.
|
JP2008542419A |
The present invention relates to a pharmaceutical composition, comprising 3±-hydroxy-3²-methoxymethyl-21-(1'-imidazolyl)-5a-pregnan-
20-one or a pharmaceutically-acceptable salt or solvate thereof, and one or more pharmaceutically-acce...
|
JP4184986B2 |
The present invention provides a method for the measurement of an analyte in biological samples whereby an uncompetitive inhibitor is coupled to a ligand and utilized in a homogeneous assay. The analyte can be a drug or drug derivative, ...
|
JP2008266348A |
To provide a caspase inhibitor which is an effective inhibitor of apoptosis and IL-1 secretion.The caspase inhibitor is represented by formula (I) (wherein Z is oxygen or sulfur; R1 is hydrogen, -CHN2, -R, -CH2OR, -CH2SR or -CH2Y; Y is a...
|
JP4145350B2 |
The invention relates to a 3 alpha -hydroxy, 17-(un)substituted derivatives of the androstane series and 3 alpha -hydroxy, 21-substituted derivatives of the pregnane series. These derivatives are capable of acting at the recently identif...
|
JP2008517993A |
The present invention relates to new compounds represented by Formula I: wherein M represents a macrolide subunit of the substructure VIII: L represents the chain of the substructure IX or XIII: -X 1 -(CH...
|
JP4089181B2 |
|
JP4085601B2 |
|
JP4066272B2 |
Methods, compositions and compounds for modulating the GABAA receptor-chloride ionophore complex to alleviate stress, anxiety, seizures, mood disorders, PMS and PND and to induce anesthesia.
|
JP4065399B2 |
Compounds of formula (I), where R is a monovalent cyclic organic group having from 3 to 15 atoms in the ring system, useful as pharmaceuticals
|
JP2008506675A |
The present invention relates to the use of a compound of formula (I) in the manufacture of a pharmaceuticals composition for cell death by photo activation therapy and the use of the compounds in the prevention and/or treatment of cancer.
|
JP4039683B2 |
A codrug composition of at least two drug compounds covalently linked to one another via a labile bond to form a single codrug composition, and methods of use of the codrug for the treatment of various medical conditions. The codrug may ...
|
JP2007537131A |
Pharmaceutical compositions for and methods of preventing infection or treating an individual who has been identified as being infected with a Flavivirus, Pestivirus, picornovirus or coronavirus such as HCV, GB virus B, JEV, WNV, CSFV, B...
|
JP2007537167A |
The present invention provides methods of preventing and treating pain, by modulating, e.g. inhibiting, the activity, function and/or expression of a PLCγ in a subject. The invention further relates to methods of identifying agents capa...
|
JP4023820B2 |
The invention concerns pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives as active ingredients which carry a group of the general formulaat their C3 position whereinR is a R<1>R<2>N group whereinR<1 >and R<2 >are ...
|
JP4021327B2 |
The invention relates to compounds of formula (I): wherein R is ethyl, propyl or allyl, and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof. The compounds of formula (I) are useful as FXR agonists.
|
JP4008024B2 |
Methods and compositions for interacting with the GABAA receptor complex to induce sleep in humans using certain 5 3 alpha -hydroxy-5-reduced steroid derivatives.
|
JP2007530652A |
The present invention relates to the preparation of a β2 adrenergic agonist in crystalline salt form. In particular the invention relates to preparation of a crystalline salt of compound (I) in particular a crystalline monohydrochloride...
|
JP2007269815A |
To provide a compound useful as an agonist for FXR (Farsnesoid X receptor), a preparation containing such the compound, and use thereof on the therapy. The compound useful as the agonist to the FXR is a compound of formula (I) (wherein, ...
|